|
EP4279513A3
(en)
*
|
2010-11-30 |
2024-02-28 |
Chugai Seiyaku Kabushiki Kaisha |
Cytotoxicity-inducing therapeutic agent
|
|
SG11201408646VA
(en)
|
2012-07-06 |
2015-01-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
|
NZ715896A
(en)
*
|
2013-07-05 |
2022-02-25 |
Genmab As |
Humanized or chimeric cd3 antibodies
|
|
PE20210107A1
(es)
|
2013-12-17 |
2021-01-19 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso
|
|
US9751946B2
(en)
|
2014-09-12 |
2017-09-05 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
|
EP3310378B1
(en)
|
2015-06-16 |
2024-01-24 |
F. Hoffmann-La Roche AG |
Anti-cll-1 antibodies and methods of use
|
|
CN107849132B
(zh)
|
2015-06-16 |
2022-03-08 |
豪夫迈·罗氏有限公司 |
人源化的和亲和力成熟的针对FcRH5的抗体和使用方法
|
|
EP3916018A1
(en)
|
2015-06-16 |
2021-12-01 |
Genentech, Inc. |
Anti-cd3 antibodies and methods of use
|
|
EA201890305A1
(ru)
|
2015-07-15 |
2018-07-31 |
Генмаб А/С |
Гуманизированные или химерные cd3-антитела
|
|
IL319047A
(en)
|
2015-08-28 |
2025-04-01 |
Amunix Operating Inc |
Chimeric polypeptide composition and methods for its preparation and use
|
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
|
EP3252078A1
(en)
*
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
|
AU2018276419A1
(en)
*
|
2016-06-02 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Type II anti-CD20 antibody and anti-CD20/CD3 bispecific antibody for treatment of cancer
|
|
CA3037694C
(fr)
|
2016-09-30 |
2023-11-14 |
Centre National De La Recherche Scientifique |
Marqueurs cellulaires
|
|
CN109923128A
(zh)
*
|
2016-11-15 |
2019-06-21 |
基因泰克公司 |
用于用抗cd20/抗cd3双特异性抗体进行治疗的给药
|
|
JP7247091B2
(ja)
*
|
2016-12-20 |
2023-03-28 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
抗ｃｄ２０／抗ｃｄ３二重特異性抗体と４－１ｂｂ（ｃｄ１３７）アゴニストの併用療法
|
|
CN119019564A
(zh)
|
2017-08-01 |
2024-11-26 |
Ab工作室有限公司 |
双特异性抗体及其用途
|
|
AU2018309339C1
(en)
|
2017-08-04 |
2025-08-21 |
BioNTech SE |
Binding agents binding to PD-L1 and CD137 and use thereof
|
|
US11472880B2
(en)
|
2017-08-14 |
2022-10-18 |
Morphosys Ag |
Humanized antibodies for CD3
|
|
CN107501412A
(zh)
*
|
2017-10-11 |
2017-12-22 |
深圳精准医疗科技有限公司 |
突变型双特异性抗体及其应用
|
|
CN118772288A
(zh)
|
2018-02-08 |
2024-10-15 |
豪夫迈·罗氏有限公司 |
双特异性抗原结合分子和使用方法
|
|
EP3749360A1
(en)
*
|
2018-02-09 |
2020-12-16 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
|
|
CN120399075A
(zh)
|
2018-03-14 |
2025-08-01 |
诺维莫尼公司 |
抗-CD3ε抗体及其应用方法
|
|
EP3569617A1
(en)
*
|
2018-05-18 |
2019-11-20 |
Trion Research GmbH |
Pharmaceutical preparation for use in treating epstein- barr virus positive patients with reactivation phenomenon- associated diseases
|
|
CN110540593B
(zh)
*
|
2018-05-29 |
2022-05-17 |
上海药明生物技术有限公司 |
新型的抗cd3/抗cd20双特异性抗体
|
|
WO2019244107A1
(en)
*
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN109836502B
(zh)
*
|
2018-11-12 |
2021-09-07 |
浙江大学 |
一种双特异性抗体及其应用
|
|
CN113660956B
(zh)
|
2019-01-28 |
2024-10-29 |
Ab诊疗公司 |
双特异性抗体及其用途
|
|
CA3131036A1
(en)
*
|
2019-02-22 |
2020-08-27 |
Wuhan Yzy Biopharma Co., Ltd. |
Cd3 antigen-binding fragment and application thereof
|
|
EP3969907B1
(en)
*
|
2019-05-13 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
|
CN110551221B
(zh)
*
|
2019-07-02 |
2021-03-05 |
广州爱思迈生物医药科技有限公司 |
一种双特异性抗体及其制备方法与应用
|
|
EP4013509A1
(en)
*
|
2019-08-15 |
2022-06-22 |
Genmab A/S |
Pharmaceutical compositions comprising bispecific antibodies directed against cd3 and cd20 and their uses
|
|
CN111100204B
(zh)
*
|
2019-11-26 |
2022-03-11 |
山东立菲生物产业有限公司 |
靶向cd20的抗体、其制备方法和应用
|
|
KR20220113790A
(ko)
|
2019-12-13 |
2022-08-16 |
제넨테크, 인크. |
항-ly6g6d 항체 및 사용 방법
|
|
CN115768483A
(zh)
*
|
2020-01-13 |
2023-03-07 |
西纳福克斯股份有限公司 |
抗体与免疫细胞衔接器的缀合物
|
|
CN113402612A
(zh)
*
|
2020-03-17 |
2021-09-17 |
西比曼生物科技（香港）有限公司 |
靶向cd19和cd20的联合嵌合抗原受体及其应用
|
|
KR20220154757A
(ko)
*
|
2020-03-18 |
2022-11-22 |
젠맵 에이/에스 |
B7h4에 결합하는 항체
|
|
IL297986A
(en)
|
2020-05-08 |
2023-01-01 |
Genmab As |
Bispecific antibodies against cd3 and cd20
|
|
US10981996B1
(en)
|
2020-06-01 |
2021-04-20 |
Abexxa Biologics, Inc. |
Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
|
|
US11976120B2
(en)
|
2020-06-01 |
2024-05-07 |
Boehringer Ingelheim International Gmbh |
Antibodies targeting a complex comprising non-classical HLA-I and neoantigen and their methods of use
|
|
CN112062855B
(zh)
*
|
2020-08-26 |
2024-08-30 |
北京天诺健成医药科技有限公司 |
一种含有衔接器的药物治疗剂的开发和应用
|
|
AU2021342343A1
(en)
*
|
2020-09-10 |
2023-04-13 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
EP4210743A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
EP4210742A1
(en)
|
2020-09-10 |
2023-07-19 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating follicular lymphoma
|
|
BR112023004321A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma de célula b grande difusa em um sujeito humano
|
|
JP2023541858A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー／エス |
慢性リンパ球性白血病を治療するためのｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
JP2023542291A
(ja)
*
|
2020-09-10 |
2023-10-06 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
MX2023005130A
(es)
|
2020-11-04 |
2023-05-25 |
Genentech Inc |
Dosis subcutanea de anticuerpos biespecificos anti-cd20/anti-cd3.
|
|
WO2022098638A2
(en)
|
2020-11-04 |
2022-05-12 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
|
CN114656562B
(zh)
|
2020-12-23 |
2023-11-03 |
北京天广实生物技术股份有限公司 |
结合人和猴cd3的抗体及其应用
|
|
SI4284512T1
(sl)
|
2021-01-28 |
2025-06-30 |
Regeneron Pharmaceuticals, Inc. |
Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
|
|
WO2022192895A1
(en)
*
|
2021-03-10 |
2022-09-15 |
H. Lee Moffitt Cancer Center And Research Institute Inc. |
Compositions and methods to reduce therapeutic t cell toxicity
|
|
KR20230156921A
(ko)
*
|
2021-03-12 |
2023-11-15 |
젠맵 에이/에스 |
비-활성화 항체 변이체
|
|
EP4330282A1
(en)
|
2021-04-30 |
2024-03-06 |
F. Hoffmann-La Roche AG |
Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
|
|
KR20240007171A
(ko)
|
2021-05-14 |
2024-01-16 |
제넨테크, 인크. |
모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
|
|
AU2023214116A1
(en)
|
2022-01-28 |
2024-07-18 |
Genmab A/S |
Bispecific antibody against cd3 and cd20 in combination therapy for treating diffuse large b-cell lymphoma
|
|
JP2025503177A
(ja)
|
2022-01-28 |
2025-01-30 |
ジェンマブ エー／エス |
びまん性大細胞型ｂ細胞リンパ腫を治療するための併用療法におけるｃｄ３及びｃｄ２０に対する二重特異性抗体
|
|
EP4507790A1
(en)
|
2022-04-11 |
2025-02-19 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
TW202519266A
(zh)
|
2022-04-13 |
2025-05-16 |
美商建南德克公司 |
莫蘇妥珠單抗之醫藥組成物及其使用方法
|
|
WO2023198839A2
(en)
|
2022-04-13 |
2023-10-19 |
Genmab A/S |
Bispecific antibodies against cd3 and cd20
|
|
WO2024102948A1
(en)
|
2022-11-11 |
2024-05-16 |
Celgene Corporation |
Fc receptor-homolog 5 (fcrh5) specific binding molecules and bispecific t-cell engaging antibodies including same and related methods
|
|
IL321437A
(en)
*
|
2022-12-14 |
2025-08-01 |
Evolveimmune Therapeutics Inc |
Bispecific antibody fusion molecules and methods for using them
|
|
CN120857940A
(zh)
|
2023-02-17 |
2025-10-28 |
瑞泽恩制药公司 |
对cd3/taa双特异性抗体有反应的诱导型nk细胞
|
|
WO2024206884A1
(en)
|
2023-03-31 |
2024-10-03 |
AbelZeta Inc. |
Bispecific chimeric antigen receptors targeting cd20 and bcma
|
|
US20240368297A1
(en)
|
2023-04-13 |
2024-11-07 |
Genmab A/S |
Methods of treating lymphoma with bispecific antibodies against cd3 and cd20
|
|
US20240409656A1
(en)
|
2023-05-15 |
2024-12-12 |
Genmab A/S |
Methods of treating cd20 expressing b-cell cancers
|
|
TW202509073A
(zh)
|
2023-05-15 |
2025-03-01 |
丹麥商珍美寶股份有限公司 |
高度純化之依可利單抗組成物
|
|
WO2025064890A1
(en)
*
|
2023-09-20 |
2025-03-27 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules targeting cd180 and cd3 and methods of use thereof
|
|
WO2025109119A1
(en)
*
|
2023-11-22 |
2025-05-30 |
Priothera Sas |
Methods of treatment with multispecific antigen-binding proteins in combination with s1p receptor modulators
|
|
GB2641580A
(en)
|
2024-06-07 |
2025-12-10 |
T Therapeutics Ltd |
Tumour-transforming multispecific proteins
|